Kura Oncology (NASDAQ:KURA) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Kura Oncology (NASDAQ:KURA - Free Report) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning.

A number of other research firms have also issued reports on KURA. Wedbush reaffirmed an "outperform" rating and set a $36.00 target price on shares of Kura Oncology in a report on Thursday, February 27th. UBS Group cut their price objective on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, March 6th. BTIG Research cut Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday, February 6th. Scotiabank cut their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a research report on Wednesday, January 8th. Finally, Cantor Fitzgerald raised shares of Kura Oncology to a "strong-buy" rating in a research note on Tuesday, March 4th. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $25.50.

Remove Ads

Kura Oncology Price Performance

KURA stock traded down $0.09 during mid-day trading on Wednesday, reaching $7.05. 957,088 shares of the company's stock were exchanged, compared to its average volume of 1,093,070. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology has a 12-month low of $6.79 and a 12-month high of $23.48. The stock's 50 day moving average is $7.82 and its 200 day moving average is $12.00. The company has a market cap of $569.32 million, a price-to-earnings ratio of -2.99 and a beta of 0.85.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million. On average, research analysts expect that Kura Oncology will post -2.44 EPS for the current year.

Insider Activity at Kura Oncology

In related news, insider Mollie Leoni sold 4,963 shares of the business's stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares of the company's stock, valued at $694,551.11. The trade was a 5.32 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,729 shares of company stock worth $92,307. Corporate insiders own 5.50% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Kura Oncology by 7.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 131,718 shares of the company's stock worth $1,147,000 after purchasing an additional 9,050 shares during the last quarter. Woodline Partners LP lifted its holdings in Kura Oncology by 20.6% during the 4th quarter. Woodline Partners LP now owns 172,704 shares of the company's stock worth $1,504,000 after buying an additional 29,497 shares during the last quarter. Velan Capital Investment Management LP acquired a new position in shares of Kura Oncology during the 4th quarter worth about $1,306,000. Squarepoint Ops LLC purchased a new position in shares of Kura Oncology in the 4th quarter valued at about $799,000. Finally, Two Sigma Advisers LP raised its position in shares of Kura Oncology by 147.1% during the 4th quarter. Two Sigma Advisers LP now owns 242,200 shares of the company's stock worth $2,110,000 after acquiring an additional 144,201 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.